Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or
the "Company"), a clinical-stage biotech company focused on
discovery and development of novel psychedelic-derived therapeutics
to solve major under-treated health problems, today announced that
it has signed a non-binding term sheet with Dr. Glitter Pty
Ltd, a health technology company that has developed ActivCrystal™
technology, a world-first oral delivery format that encapsulates
active ingredients in crystals that are tasteless, odorless, made
from natural ingredients, and designed to be sprinkled on meals.
The two companies plan to collaborate on the development and
commercialization of Clearmind’s proprietary MEAI-based alcohol
substitute and Dr Glitter Pty Ltd’s proprietary ActivCrystal™
technology. The term sheet outlines preliminary terms that, upon
the mutual agreement of the parties, will be memorialized in a
definitive agreement that sets forth a framework for advancing
Clearmind and Dr Glitter Pty Ltd’s groundbreaking innovations.
Under the terms of the term sheet, upon the execution of the
definitive agreement, the parties will work together to develop
MEAI-based alcohol alternative aimed to naturally replicate the
known sensations from drinking alcohol without the associated
health risks or hangover. In ActivCrystal™ format, Clearmind’s
MEAI-based alcohol alternative may be sprinkled into users’ choice
of beverage or food, and dosage may be varied by users
individually. This collaboration has the potential to mark an
important milestone in Clearmind’s strategy to bring MEAI to global
markets, addressing the urgent need for innovative solutions to
combat alcohol misuse - a major contributor to countless annual
deaths worldwide.
“We are thrilled to work with ActivCrystal™ technology to
advance the development of MEAI as a safe alternative to alcohol,”
said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. “In parallel
to advancing our clinical program with MEAI, we are actively
developing our alcohol alternative product, designed to provide
some of the enjoyable sensations and experiences associated with
alcohol, without the alcohol itself. By offering a solution that
adults can enjoy without the harmful effects of alcohol, we aim to
transform the landscape of social drinking. We believe that
partnering with innovative companies in this field is the right
approach to drive this change forward.”
“Our mission is to empower happy, healthy living.” said Jade
Diep, CEO of Dr Glitter Pty Ltd, “Our team is passionate about
making alcohol-alternatives more accessible and easy to consume.
The ActivCrystal™ format allows MEAI to be consumed in a variety of
beverages that can be chosen by the user, and based on their
individual preferences or what is being served in their social
setting. We are excited to partner with Clearmind and use our
company’s technology to support those who suffer from alcohol use
disorder and create a new product in the non-alcoholic
industry.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech
company focused on the discovery and development of novel
psychedelic-derived therapeutics to solve widespread and
underserved health problems, including alcohol use disorder. Its
primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines,
foods or supplements.
The Company’s intellectual portfolio currently consists of
nineteen patent families including 29 granted patents. The Company
intends to seek additional patents for its compounds whenever
warranted and will remain opportunistic regarding the acquisition
of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the
symbol "CMND" and the Frankfurt Stock Exchange under the symbol
“CWY0.”
For further information
visit: https://www.clearmindmedicine.com or contact:
Investor Relations invest@clearmindmedicine.com
Telephone: (604) 260-1566 US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
About Dr Glitter Pty Ltd
Dr Glitter Pty Ltd is a health technology company that has
developed ActivCrystal™ technology, a world-first oral delivery
format that encapsulates active ingredients in crystals that are
tasteless, odourless, made from natural ingredients, and designed
to be sprinkled on meals.
The Company has submitted its international patent application
for the use cases, manufacturing processes, and compositions of
ActivCrystals™. The product format has been commercialised under
the Dr Glitter™ brand, and has extensive potential applications in
dietary supplements, pet supplements, therapeutic drugs, and in
geriatric and paediatric medicine. The company also intends to
license its product format to brands and manufacturers
globally.
For further information, please contact
info@activcrystal.com
To learn more about the Dr Glitter™ brand, please visit
www.drglitter.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act and
other securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar
expressions or variations of such words are intended to identify
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses the execution of
definitive agreements with Dr. Glitter PTY Ltd., the potential
collaboration and partnership with Dr. Glitter PTY Ltd., its
strategy to bring MEAI to global markets, its aims to transform the
landscape of social drinking and its belief that that partnering
with innovative companies in the alcohol alternative and substitute
market is the right approach to change the face of social
drinking. The Company cannot assure that any patent will
issue as a result of a pending patent application or, if issued,
whether it will issue in a form that will be advantageous to the
Company. Forward-looking statements are not historical facts, and
are based upon management’s current expectations, beliefs and
projections, many of which, by their nature, are inherently
uncertain. Such expectations, beliefs and projections are expressed
in good faith. However, there can be no assurance that management’s
expectations, beliefs and projections will be achieved, and actual
results may differ materially from what is expressed in or
indicated by the forward-looking statements. Forward-looking
statements are subject to risks and uncertainties that could cause
actual performance or results to differ materially from those
expressed in the forward-looking statements. For a more detailed
description of the risks and uncertainties affecting the Company,
reference is made to the Company’s reports filed from time to time
with the Securities and Exchange Commission (“SEC”), including, but
not limited to, the risks detailed in the Company’s annual report
on Form 20-F for the fiscal year ended October 31, 2023 filed with
the SEC. Forward-looking statements speak only as of the date the
statements are made. The Company assumes no obligation to update
forward-looking statements to reflect actual results, subsequent
events or circumstances, changes in assumptions or changes in other
factors affecting forward-looking information except to the extent
required by applicable securities laws. If the Company does update
one or more forward-looking statements, no inference should be
drawn that the Company will make additional updates with respect
thereto or with respect to other forward-looking statements.
References and links to websites have been provided as a
convenience, and the information contained on such websites is not
incorporated by reference into this press release. Clearmind is not
responsible for the contents of third-party websites.
Clearmind Medicine (NASDAQ:CMND)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Clearmind Medicine (NASDAQ:CMND)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024